Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
The study is intended to collect specimens to support the application of genome analysis technologies, including large-scale genome sequencing. This study will ultimately provide cancer researchers with specimens that they can use to develop comprehensive catalogs of genomic information on at least 50 types of human cancer. The study will create a resource available to the worldwide research community that could be used to identify and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. This study will be a competitive enrollment study conducted at multiple institutions.
Checked against the public recordLast updated Feb 28, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Global BioClinical
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Any adult age * Any sex * Able to provide consent for surplus tissue and/or blood donation * Diagnosed with one of the cancer indications listed below: * Scheduled to undergo surgical resection of tumor (exception for hematological cancers) * Have not yet received treatment for cancer Exclusion Criteria: * Not diagnosed with required cancer indication * Not scheduled to undergo surgical resection of the tumor * Have already received cancer treatment (such as chemotherapy, radiation, surgery) for the current cancer or a previously diagnosed cancer * Not able to donate an adequate volume of blood to meet minimum requirements CANCER INDICATIONS: 1. Bladder Cancer - Urothelial carcinoma - nonpapillary 2. Bladder Cancer - Urothelial carcinoma - papillary 3. Brain Cancer - Astrocytoma 4. Brain Cancer - Glioblastoma 5. Brain Cancer - Medulloblastoma 6. Breast Cancer - Ductal Carcinoma 7. Breast Cancer - Lobular Carcinoma 8. Cervical Cancer - Squamous Cell Carcinoma 9. Colorectal Cancer - Adenocarcinoma 10. Esophageal Cancer - Adenocarcinoma 11. Gastric Cancer 12. Head and Neck Cancer - Squamous Cell Carcinoma 13. Hematologic Cancer - Acute Lymphocytic Leukemia (ALL) 14. Hematologic Cancer - Acute Myeloid Leukemia (AML) 15. Hematologic Cancer - Chronic Lymphocytic Leukemia (CLL) 16. Hematologic Cancer - Diffuse Large B-cell Lymphoma 17. Hematologic Cancer - Multiple Myeloma (MM) 18. Hematologic Cancer - Non-Hodgkins Lymphoma (NHL) 19. Kidney Cancer - Papillary Carcinoma 20. Kidney Cancer - Renal cell Carcinoma 21. Liver Cancer - Hepatocellular Carcinoma 22. Lung Cancer - Adenocarcinoma 23. Lung Cancer - Squamous Cell Cancer 24. Melanoma 25. Pancreatic Cancer - Ductal Adenocarcinoma 26. Prostate Cancer - Adenocarcinoma 27. Sarcomas 28. Thyroid Cancer - Follicular Carcinoma 29. Thyroid Cancer - Papillary Carcinoma 30. Uterine Cancer - Endometrial Carcinoma
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- GBCSeattle, Washington
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 28, 2023. Always confirm current availability with the study team.